Mark Roskey Net Worth

The estimated Net Worth of Mark T. Roskey is at least $922 Тысяча dollars as of 1 April 2022. Mr. Roskey owns over 171 units of Quanterix Corp stock worth over $269,463 and over the last 6 years he sold QTRX stock worth over $332,833. In addition, he makes $319,696 as Senior Vice President - Commercial and Accelerator at Quanterix Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Roskey QTRX stock SEC Form 4 insiders trading

Mark has made over 44 trades of the Quanterix Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 171 units of QTRX stock worth $5,094 on 1 April 2022.

The largest trade he's ever made was selling 5,093 units of Quanterix Corp stock on 30 March 2020 worth over $91,623. On average, Mark trades about 760 units every 22 days since 2018. As of 1 April 2022 he still owns at least 22,325 units of Quanterix Corp stock.

You can see the complete history of Mr. Roskey stock trades at the bottom of the page.

Mark Roskey biography

Mark T. Roskey serves as Senior Vice President - Commercial and Accelerator of the Company. He has been our Senior Vice President, Commercial and Accelerator since March 2019 and served as Senior Vice President and General Manager of Applications and Reagents from September 2014 to March 2019. Prior to joining us, Dr. Roskey served as Vice President and General Manager of the America's Sales and Service organization in PerkinElmer's Life Science and Technologies Division from December 2011 to September 2014. PerkinElmer is a global life science company. Prior to PerkinElmer, Dr. Roskey served as Senior Vice President of Biology Research and Development at Caliper Life Sciences, Inc. from March 2009 to November 2011, when it was acquired by PerkinElmer. At Caliper Life Sciences, Inc., Dr. Roskey served as Senior Vice President of Applied Biology Research from 2008 to 2011 and Vice President of Worldwide Marketing from July 2003 to 2008. Prior to that, Dr. Roskey served as Vice President of Worldwide Marketing for Zymark Corporation, a laboratory automation company, from December 2001 to August 2003 when it was acquired by Caliper Life Sciences, Inc. Prior to that, Dr. Roskey served as Director of Marketing at Applied Biosystems, Inc. Dr. Roskey completed a postdoctoral fellowship in molecular immunobiology at the Harvard Medical School and has a Ph.D. in microbiology from the University of Notre Dame and a B.S. in biology from Framingham State University.

What is the salary of Mark Roskey?

As the Senior Vice President - Commercial and Accelerator of Quanterix Corp, the total compensation of Mark Roskey at Quanterix Corp is $319,696. There are 7 executives at Quanterix Corp getting paid more, with E. Kevin Hrusovsky having the highest compensation of $3,631,000.

How old is Mark Roskey?

Mark Roskey is 60, he's been the Senior Vice President - Commercial and Accelerator of Quanterix Corp since 2019. There are 7 older and 12 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.

What's Mark Roskey's mailing address?

Mark's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.

Insiders trading at Quanterix Corp

Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister и Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.

What does Quanterix Corp do?

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).

Complete history of Mr. Roskey stock trades at Quanterix Corp

Quanterix Corp executives and stock owners

Quanterix Corp executives and other stock owners filed with the SEC include:

• E. Kevin Hrusovsky,
  Chairman of the Board, President, Chief Executive Officer
• John Fry,
  General Counsel, Secretary
• Amol Chaubal,
  Chief Financial Officer
• E. Kevin Hrusovsky,
  Chairman & CEO
• Dawn Mattoon,
  Senior Vice President - Research Products
• David Duffy,
  Senior Vice President, Research & Development and Chief Technology Officer
• Sarah Hlavinka,
  Independent Director
• Mark Roskey,
  Senior Vice President - Commercial and Accelerator
• Martin Madaus,
  Lead Independent Director
• Paul Meister,
  Independent Director
• Keith Crandell,
  Independent Director
• Marijn Dekkers,
  Independent Director
• David Walt,
  Independent Director
• Dr. David R. Walt Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• William Geist,
  Chief Operating Officer
• Dr. Masoud Toloue Ph.D.,
  Pres, CEO & Director
• Dr. Dawn R. Mattoon Ph.D.,
  Sr. VP of Diagnostics
• Dr. Mark T. Roskey Ph.D.,
  Sr. VP of Strategic Partnerships
• Dr. David C. Duffy Ph.D.,
  Sr. VP of R&D and CTO
• Michael A. Doyle,
  CFO & Treasurer
• Masoud Toloue,
  Pres & Head of Diagnostics Bus.
• David Panzerella,
  VP of Sales
• William Geist,
  Chief Operating Officer
• Bruce J. Bal,
  VP of Operations, Service & Quality
• John J. Fry,
  Gen. Counsel & Corp. Sec.
• Brian J Blaser,
  
• Shawn Stetson,
  Interim CFO and Treasurer
• Venture Fund Vi Lparch Vent...,
  
• Ventures Fund 2004 L P Flag...,
  
• Capital Venture Investors, ...,
  
• Ernest Orticerio,
  SVP Finance and Corporate Dev
• Douglas G. Cole,
  
• John M Connolly,
  
• Jackson Streeter,
  SVP, Corp Dev & Strategy
• Bruce J Bal,
  VP of Ops, Service and Quality
• Joseph Driscoll,
  Chief Financial Officer
• Amee Desjourdy,
  Chief Human Resource Officer
• Laurie J Olson,
  
• Michael A Doyle,
  CFO and Treasurer
• Masoud Toloue,
  President & CEO
• Karen Flynn,
  
• William P Donnelly,
  
• Vandana Sriram,
  Chief Financial Officer
• Jeffrey Thomas Elliott,